Equities

Formosa Pharmaceuticals Inc

6838:TAI

Formosa Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)38.95
  • Today's Change0.05 / 0.13%
  • Shares traded167.20k
  • 1 Year change-22.87%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Formosa Pharmaceuticals Inc is a Taiwan-based company mainly engaged in the development of early drug candiate and pre-clinical drug products. The Company also conducts the research and development of nanotechnology platform and dosage form design, and uses the patented nano platform to overcome the challenges of low dissociation rate and poor bioavailability in the development of pharmaceutical dosage forms. In the research and development projects, the ophthalmic drug APP13007 has entered the phase III clinical trial stage, and its indications are anti-ocular postoperative inflammation, and its main appeal is to reduce postoperative inflammation and pain. TSY-0110 has entered the preclinical stage to develop antibody-drug conjugate (ADC) to cure breast cancer. The innovative small molecule compound MPT0E028 has completed the first phase of clinical trials and is expected to be used in the field of anti-cancer therapy.

  • Revenue in TWD (TTM)137.46m
  • Net income in TWD-200.59m
  • Incorporated2010
  • Employees--
  • Location
    Formosa Pharmaceuticals Inc8F-6, No. 57, Fuxing North RoadTAIPEI 105TaiwanTWN
  • Phone+886 227557659
  • Fax+886 227553023
  • Websitehttps://www.formosapharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nang Kuang Pharmaceutical Co Ltd2.14bn122.15m4.36bn552.0035.751.8714.342.041.211.2121.1523.090.57882.087.71--3.316.754.929.6433.2434.775.7212.220.668414.940.179582.7410.816.92-43.6314.4119.5110.76
Sinphar Pharmaceutical Co Ltd3.04bn332.79m5.63bn984.0016.951.779.841.851.831.8316.7817.560.49012.346.85--5.29-0.01476.91-0.020338.5137.4910.80-0.03441.5819.250.343579.703.725.9867.01111.883.3160.95
Cenra Inc8.94bn371.76m5.66bn1.40k25.410.7567.830.63381.501.5034.2850.260.71062.155.73--2.973.694.294.9637.1036.564.185.500.7054--0.297652.771.402.50-32.51-2.723.57-8.97
Formosa Pharmaceuticals Inc137.46m-200.59m5.87bn----3.66--42.72-1.49-1.491.0210.62-----------40.34---44.2184.63---145.95-2,488.28----0.0167--2,270.49--20.75---42.98--
Panion & BF Biotech Inc2.04bn121.33m7.66bn321.0063.144.0726.303.761.411.4123.7321.940.65461.729.66--3.904.085.725.6352.4352.375.965.930.880416.870.2717111.06-21.545.96-57.65-13.4735.39-3.23
Data as of Nov 22 2024. Currency figures normalised to Formosa Pharmaceuticals Inc's reporting currency: Taiwan Dollar TWD

Institutional shareholders

0.05%Per cent of shares held by top holders
HolderShares% Held
SSgA Funds Management, Inc.as of 07 Nov 202469.67k0.05%
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.